Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded by Roth Capital to “Strong-Buy” Rating

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by research analysts at Roth Capital to a “strong-buy” rating in a research report issued on Friday,Zacks.com reports.

Several other equities research analysts have also commented on RVPH. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Friday. EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd. Finally, Roth Mkm started coverage on Reviva Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $7.00 price target for the company. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $11.25.

Reviva Pharmaceuticals Stock Up 0.5 %

RVPH stock opened at $1.88 on Friday. The stock has a market cap of $62.87 million, a PE ratio of -1.69 and a beta of -0.12. The firm’s 50-day simple moving average is $1.56 and its 200 day simple moving average is $1.29. Reviva Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $4.83.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC raised its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.